



## **Duvelisib**

Catalog No: tcsc0888

Available Sizes	
Size: 5mg	
Size: 10mg	
Size: 50mg	
Size: 100mg	
Size: 200mg	
Size: 500mg	
Size: 1g	
Size: 2g	
Specifications	
CAS No: 1201438-56-3	
Formula: C <sub>22</sub> H <sub>17</sub> CIN <sub>6</sub> O	
Pathway: PI3K/Akt/mTOR	
Target: PI3K	
Purity / Grade: >98%	
Solubility:	





DMSO : ≥ 41 mg/mL (98.35 mM)

## **Alternative Names:**

IPI-145;INK1197

## **Observed Molecular Weight:**

416.86

## **Product Description**

Duvelisib is a selectivite **p1006** inhibitor with IC<sub>50</sub> of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110 $\delta$ , P110 $\gamma$ , p110 $\beta$  and p110 $\alpha$ , respectively.

IC50 & Target: IC50: 2.5 nM (p110 $\delta$ ), 27.4 nM (p110 $\gamma$ ), 85 nM (p110 $\beta$ ), 1602 nM (p110 $\alpha$ )<sup>[2]</sup>

In Vitro: PI3K $\delta$  and PI3K $\gamma$  inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells<sup>[1]</sup>

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!